{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:58:56Z","timestamp":1790758736416,"version":"4.1.0"},"reference-count":24,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"unspecified","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031022","name":"Center for Cancer Research","doi-asserted-by":"publisher","award":["Contract No. 75N910D00024"],"award-info":[{"award-number":["Contract No. 75N910D00024"]}],"id":[{"id":"10.13039\/100031022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031022","name":"Center for Cancer Research","doi-asserted-by":"publisher","award":["ZIA BC 011584"],"award-info":[{"award-number":["ZIA BC 011584"]}],"id":[{"id":"10.13039\/100031022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,8,16]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ovarian cancer is the most lethal gynecological malignancy and lacks therapeutic options in the recurrent setting. We previously determined the safety and initial clinical activity of intraperitoneal autologous monocytes with interferon gamma and interferon alpha (AMIGA) in women with recurrent, platinum-resistant ovarian cancer, but not all enrolled patients showed benefit, warranting further analysis to understand and improve this therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Experimental design<\/jats:title>\n                    <jats:p>Bulk RNA sequencing and single-cell RNA sequencing were conducted on circulating immune cells from patients with ovarian cancer treated with AMIGA. Primary human monocytes and T cells were isolated from healthy donors and used in co-cultures with ovarian cancer cell lines to test the effects of AMIGA on T-cell recruitment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Comparing circulating immune cells from long-term responders to non-responders from our clinical trial revealed an increased cell-mediated immune response in long-term responders. T cells in AMIGA-treated patients also upregulated unique, specific T cell receptor-beta chain genes. Bulk RNA-seq of peripheral blood mononuclear cells revealed AMIGA-driven upregulation of CXCL10 and CCL2 mRNA. An increase in these chemokines was consistently reflected in patients\u2019 malignant ascites. Finally, in vitro models validated increases in CXCL10 as well as CCL2, and demonstrated that these chemokines exert variable effects on T-cell chemotaxis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The AMIGA-driven effects on T cell recruitment and upregulation of specific T cell receptor-beta chain genes support the development of future combination therapies of intraperitoneal AMIGA and T cell-based immunotherapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2026-014938","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:10:13Z","timestamp":1788786613000},"page":"e014938","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Transcriptomic analysis of a phase 1 trial for intraperitoneal monocytes plus IFNs in ovarian cancer reveals support and recruitment of cell-mediated immunity"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct02948426","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7849-1984","authenticated-orcid":false,"given":"Franklin","family":"Ning","sequence":"first","affiliation":[{"name":"Women\u2019s Malignancies Branch, National Cancer Institute Center for Cancer Research, Bethesda, Maryland, USA"},{"name":"Department of Internal Medicine, University of Maryland Baltimore, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7730-2611","authenticated-orcid":false,"given":"Emily","family":"San Andres-Montalvan","sequence":"additional","affiliation":[{"name":"Women\u2019s Malignancies Branch, National Cancer Institute Center for Cancer Research, Bethesda, Maryland, USA"},{"name":"Department of Pathobiology and Laboratory Medicine, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7185-5597","authenticated-orcid":false,"given":"Thomas J","family":"Meyer","sequence":"additional","affiliation":[{"name":"Advanced Biomedical Computational Science, National Cancer Institute Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA"},{"name":"CCR Collaborative Bioinformatics Resource (CCBR), Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Kaczanowska","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch, Center for Cancer Research, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosie","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch, National Cancer Institute, Bethesda, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina M","family":"Annunziata","sequence":"additional","affiliation":[{"name":"Women\u2019s Malignancies Branch, National Cancer Institute Center for Cancer Research, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"2026093001151333000_14.9.e014938.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21871"},{"key":"2026093001151333000_14.9.e014938.2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx441"},{"key":"2026093001151333000_14.9.e014938.3","doi-asserted-by":"crossref","first-page":"934","DOI":"10.3390\/cancers11070934","article-title":"Ovarian cancer stem cells: role in metastasis and opportunity for therapeutic targeting","volume":"11","author":"Zong","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2026093001151333000_14.9.e014938.4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.604084","article-title":"Driving immune responses in the ovarian tumor microenvironment","volume":"10","author":"Ning","year":"2020","journal-title":"Front Oncol"},{"key":"2026093001151333000_14.9.e014938.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.3397"},{"key":"2026093001151333000_14.9.e014938.6","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ymthe.2019.11.028","article-title":"CAR T cells targeting MISIIR for the treatment of ovarian cancer and other gynecologic malignancies","volume":"28","author":"Rodriguez-Garcia","year":"2020","journal-title":"Mol Ther"},{"key":"2026093001151333000_14.9.e014938.7","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ygyno.2018.10.008","article-title":"Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials","volume":"151","author":"Hinchcliff","year":"2018","journal-title":"Gynecol Oncol"},{"key":"2026093001151333000_14.9.e014938.8","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxw020"},{"key":"2026093001151333000_14.9.e014938.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.06.010"},{"key":"2026093001151333000_14.9.e014938.10","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701019"},{"key":"2026093001151333000_14.9.e014938.11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-1893"},{"key":"2026093001151333000_14.9.e014938.12","doi-asserted-by":"publisher","DOI":"10.14806\/ej.17.1.200"},{"key":"2026093001151333000_14.9.e014938.13","doi-asserted-by":"publisher","DOI":"10.1016\/J.CELL.2021.04.048"},{"key":"2026093001151333000_14.9.e014938.14","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-019-1874-1","article-title":"Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression","volume":"20","author":"Hafemeister","year":"2019","journal-title":"Genome Biol"},{"key":"2026093001151333000_14.9.e014938.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2010.12.017"},{"key":"2026093001151333000_14.9.e014938.16","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-017-1349-1","article-title":"xCell: digitally portraying the tissue cellular heterogeneity landscape","volume":"18","author":"Aran","year":"2017","journal-title":"Genome Biol"},{"key":"2026093001151333000_14.9.e014938.17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02035"},{"key":"2026093001151333000_14.9.e014938.18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00819","article-title":"Emerging role of lymphocyte antigen-6 family of genes in cancer and immune cells","volume":"10","author":"Upadhyay","year":"2019","journal-title":"Front Immunol"},{"key":"2026093001151333000_14.9.e014938.19","doi-asserted-by":"crossref","unstructured":"Kassianos AJ , Jongbloed SL , Hart DNJ , et al . Isolation of human blood DC subtypes. In 2010;45\u201354. doi:10.1007\/978-1-60761-421-0_3","DOI":"10.1007\/978-1-60761-421-0_3"},{"key":"2026093001151333000_14.9.e014938.20","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.28811"},{"key":"2026093001151333000_14.9.e014938.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2009.08.021"},{"key":"2026093001151333000_14.9.e014938.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.11350"},{"key":"2026093001151333000_14.9.e014938.23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01022"},{"key":"2026093001151333000_14.9.e014938.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2016.05.028"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2026-014938","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:15:25Z","timestamp":1790756125000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2026-014938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":24,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,7]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/jitc-2026-014938"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2026-014938","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}